While no resource is perfect, it is worthwhile to familiarize yourself with some contemporary methodology and predictive tools to help determine life expectancy in localized prostate cancer patients.
Casdatifan showed a 35% confirmed ORR in the 100 mg cohort, with median PFS not reached, indicating promising efficacy. The pooled analysis revealed a 31% ORR and a median PFS of 12.2 months, ...
EG110A targets type C sensory neurons to manage neurogenic detrusor overactivity-related incontinence, preserving other bladder controls. Fast track designation by the FDA allows EG110A to benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback